hepatitis b

Chronic hepatitis B virus infection affects approximately 300 million people globally and is a leading cause of cirrhosis and hepatocellular carcinoma. Nucleos(t)ide analogues effectively suppress viral replication but rarely achieve functional cure. Clinical trials targeting viral cccDNA, surface antigen clearance, and immune restoration are pursuing finite-duration curative regimens.